- Historical context0th pct
- Persistence6 periods
- Independent evidence1 group
· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTAtriCure, Inc.'s latest supported as-filed period reports revenue of $153.6M. Every value below links to its SEC accession and metric lineage.
Unusual transitions and combinations worth inspecting—not forecasts or recommendations.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 39.71% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.45% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 14.45% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 12.83% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 54.64% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 77.23% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 12.8%; Operating margin moved 1084 bp higher; Operating income changed across a sign change.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 42.4%; Operating cash flow increased 2.7%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 41.5%; Capex / revenue moved 50 bp higher.
2 evidence-backed componentsWorking capital changed +30.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ATRC · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001336063-26-000008SEC ↗4Sep 4, 2026Period Sep 2, 20260001336063-26-000006SEC ↗4Aug 26, 2026Period Aug 24, 20260001861996-26-000006SEC ↗4Aug 7, 2026Period Aug 5, 20260001566083-26-000006SEC ↗4Aug 7, 2026Period Aug 5, 20260001796057-26-000010SEC ↗4Aug 3, 2026Period Jul 30, 20260001230584-26-000008SEC ↗4Jul 30, 2026Period Jul 28, 20260001862458-26-000011SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 8, 2026Filed Sep 10, 2026 | Privitera SalvatoreChief Technical Officer | Open Market SaleDirect | 3,657 | $55 | $201,135 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 4, 2026 | Privitera SalvatoreChief Technical Officer | Open Market SaleDirect | 7,763 | $53 | $407,558 | Form 4 ↗ |
| Aug 24, 2026Filed Aug 26, 2026 | Dahlquist Karl S.Chief Legal Officer | Open Market SaleDirect | 9,370 | $49 | $458,099 | Form 4 ↗ |
| Aug 5, 2026Filed Aug 7, 2026 | Prange KarenDirector | Open Market SaleDirect | 3,564 | $39 | $138,283 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 6.29% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 17.19% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 8.02% · OPTIONAL
Current assets changed +27.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed +571 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Trade receivables changed +21.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +11.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed +1084 basis points from the comparable as-filed period.
Cash & equivalents changed +42.4% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001205069-26-000005| Yuen MaggieDirector |
| Open Market SaleDirect |
| 3,500 |
| $38 |
| $134,470 |
| Form 4 ↗ |
| Jul 30, 2026Filed Aug 3, 2026 | CARREL MICHAEL HPresident, CEO, & Director | GiftDirect | 700 | $0 | $0 | Form 4 ↗ |
| Jul 30, 2026Filed Aug 3, 2026 | CARREL MICHAEL HPresident, CEO, & Director | GiftDirect | 4,000 | $0 | $0 | Form 4 ↗ |
| Jul 29, 2026Filed Jul 30, 2026 | Noznesky Justin JChief Mktg & Strategy Officer | Open Market SaleDirect | 6,182 | $39 | $239,862 | Form 4 ↗ |
| Jul 28, 2026Filed Jul 30, 2026 | WEHRWEIN SVENDirector | Option ExerciseDirect | 25,000 | $0 | $0 | Form 4 ↗ |
| Jul 28, 2026Filed Jul 30, 2026 | WEHRWEIN SVENDirector | Open Market SaleDirect | 25,000 | $38 | $946,000 | Form 4 ↗ |
| Jul 28, 2026Filed Jul 30, 2026 | WEHRWEIN SVENDirector | Option ExerciseDirect | 25,000 | $20 | $498,750 | Form 4 ↗ |
| Jul 28, 2026Filed Jul 30, 2026 | Doraiswamy VinayakChief Scientific Officer | Open Market SaleDirect | 6,000 | $39 | $233,280 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | Dahlquist Karl S.Chief Legal Officer | Grant Or AwardDirect | 636 | $24 | $15,124 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | Seith Douglas JChief Operating Officer | Grant Or AwardDirect | 527 | $24 | $12,532 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | Privitera SalvatoreChief Technical Officer | Grant Or AwardDirect | 636 | $24 | $15,124 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | CARREL MICHAEL HPresident, CEO, & Director | Grant Or AwardDirect | 636 | $24 | $15,124 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | Doraiswamy VinayakChief Scientific Officer | Grant Or AwardDirect | 636 | $24 | $15,124 | Form 4 ↗ |